度伐利尤单抗致免疫相关性肺炎1例
One Case of Immune-Related Pneumonia Caused by Dulvalizumab
DOI: 10.12677/ACM.2022.125643, PDF,   
作者: 张展昱, 孙晓琳, 许林宗, 李晓梅*：山东大学，山东 济南；山东省立医院肿瘤治疗中心，山东 济南；戴洪海, 杨 宁：山东第一医科大学附属省立医院肿瘤治疗中心，山东 济南
关键词: 免疫疗法；度伐利尤单抗；肺炎；药物不良反应；Immunotherapy； Dulvalizumab； Pneumonia； Adverse Drug Reactions
摘要: 中枢神经系统中免疫细胞的存在为肿瘤患者进行免疫治疗带来希望。其中，部分免疫检查点抑制剂已应用于临床，程序性死亡配体-1的抑制剂通过激活免疫系统发挥抗肿瘤作用。近年来免疫治疗在肿瘤治疗中的地位越来越高，度伐利尤单抗也应用于小细胞肺癌治疗，但随之而来的免疫抑制剂导致的免疫相关性肺炎受到人们关注。本文为1例度伐利尤单抗致免疫相关性肺炎的相关病例报道。
Abstract: The presence of immune cells in the central nervous system holds promise for immunotherapy of small-cell lung cancer. Some of these immune checkpoint inhibitors are already in clinical use, and inhibitors of programmed cell death-Ligand 1 exert anti-tumor effects by activating the immune system. In recent years, immunotherapy has become more and more important in tumor treatment, and dulvalizumab is also used in the treatment of small cell lung cancer, but the consequent immunosuppression-induced immune-associated pneumonia has received attention. In this paper, we present a case report related to immune-associated pneumonia caused by dulvalizumab.
文章引用：张展昱, 戴洪海, 杨宁, 孙晓琳, 许林宗, 李晓梅. 度伐利尤单抗致免疫相关性肺炎1例[J]. 临床医学进展, 2022, 12(5): 4451-4455. https://doi.org/10.12677/ACM.2022.125643

参考文献

[1] Sun, X., Roudi, R., Dai, T., et al. (2019) Immune-Related Adverse Events Associated with Programmed Cell Death Protein-1 and Programmed Cell Death Ligand 1 Inhibitors for Non-Small Cell Lung Cancer: A PRISMA Systematic Review and Meta-Analysis. BMC Cancer, 19, Article No. 558. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, C., Wu, B., Zhang, C., et al. (2021) Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: An Updated Comprehensive Disproportionality Analysis of the FDA Adverse Event Reporting System. International Immunopharmacology, 95, Article ID: 107498. [Google Scholar] [CrossRef] [PubMed]
[3] 陈康, 孙步彤. PD-1/PD-L1抑制剂在晚期肿瘤患者中的相关肺炎发生率和发生风险: 一项荟萃分析[J]. 中国肺癌杂志, 2020, 23(11): 927-940.
[4] Stewart, R., Morrow, M., Hammond, S.A., et al. (2015) Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunology Research, 3, 1052-1062. [Google Scholar] [CrossRef] 
[5] Goldman, J.W., Dvorkin, M., Chen, Y., Reinmuth, N., et al. (2021) Durvalumab, with or without Tremelimumab, plus Platinum-Etoposide versus Platinum-Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 51-65. [Google Scholar] [CrossRef] 
[6] Remon, J., Aldea, M., Besse, B., et al. (2021) Small Cell Lung Cancer: A Slightly Less Orphan Disease after Immunotherapy. Annals of Oncology, 32, 698-709. [Google Scholar] [CrossRef] [PubMed]
[7] Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., et al. (2019) Durvalumab plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet, 394, 1929-1939. [Google Scholar] [CrossRef] 
[8] Khoja, L., Day, D., Wei-Wu, C.T., et al. (2017) Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A System-atic Review. Annals of Oncology, 28, 2377-2385. [Google Scholar] [CrossRef] [PubMed]
[9] Naidoo, J., Wang, X., Woo, K.M., Iyriboz, T., et al. (2017) Pneu-monitis in Patients Treated with Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology, 35, 709-717. [Google Scholar] [CrossRef] 
[10] Delaunay, M., Cadranel, J., Lusque, A., et al. (2017) Im-mune-Checkpoint Inhibitors Associated with Interstitial Lung Disease in Cancer Patients. European Respiratory Journal, 50, No. 2. [Google Scholar] [CrossRef] [PubMed]
[11] Friedman, C.F., Proverbs-Singh, T.A. and Postow, M.A. (2016) Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncology, 2, 1346-1353. [Google Scholar] [CrossRef] [PubMed]
[12] Suresh, K., Voong, K.R., Shankar, B., et al. (2018) Pneu-monitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of Thoracic Oncology, 13, 1930-1939. [Google Scholar] [CrossRef] [PubMed]

为你推荐